TAUROURSO DEOXYCHOLIC ACID IN CYSTIC FIBROSIS LIVER DISEASE

牛磺酰脱氧胆酸在囊性纤维化肝病中的作用

• 批准号: 6264293
• 负责人: MICHAEL R. NARKEWICZ
• 金额: $ 1.99万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264293
• 关键词: chenodeoxycholate; clinical research; combination chemotherapy; cystic fibrosis; dosage; feces analysis; human subject; human therapy evaluation; lipid metabolism; metabolism disorder chemotherapy; pharmacokinetics; serum; taurine; tocopherols; ursodeoxycholate

The two specific aims of this multicenter are to a) determine the optimum dose of TUCDA required to achieve maximal bioavailability, defined by biliary enrichment in TUDCA, and 2) perform a double blind crossover study of TUDCA and UDCA in patients with CF associated liver disease comparing: biliary bile acid composition and effect on serum biochemistries in vitamin E status and fecal fat excretion.

该多中心的两个具体目标是 a) 确定达到最大生物利用度所需的 TUCDA 最佳剂量（通过 TUDCA 中的胆汁富集来定义），以及 2) 在 CF 相关肝病患者中进行 TUDCA 和 UDCA 双盲交叉研究，比较：胆汁胆汁酸组成以及对维生素 E 状态和粪便脂肪排泄的血清生化的影响。